Aug 02
Hepatitis C (HCV)–Pipeline Assessment and Market Forecasts to 2016
Mon, 08/02/2010 - 18:20 — admin
Hepatitis C is Big Business for Pharmaceutical Companies.
GlobalData’s analysis suggests that the global hepatitis C market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the next seven years to reach $8.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the hepatitis C market.
© Lloyd Wright {dot} org